16:35 EDT Metagenomi (MGX) sees cash, equivalents supporting operations into 2027
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGX:
- Metagenomi price target lowered to $7 from $14 at H.C. Wainwright
- Biotech stocks slide as Marks resignation seen being negative for sector
- BMO says Peter Marks resignation ‘significant negative’ for biotech
- Metagenomi Faces Legal Battle Over Alleged Misleading Statements in Moderna Collaboration
- Metagenomi, Inc. Reports 2024 Financial Results and Pipeline Progress
